DAFNE (Dose Adjustment for Normal Eating): structured education in insulin replacement therapy for type 1 diabetes

H David McIntyre
Med J Aust 2006; 184 (7): . || doi: 10.5694/j.1326-5377.2006.tb00261.x
Published online: 3 April 2006

This European approach to insulin management is now being introduced in Australia

Since the publication of the Diabetes Control and Complications Trial (DCCT) in 1993,1 improved glycaemic control in type 1 diabetes has been acknowledged as a desirable goal in theory, but frustratingly difficult to achieve in practice. Although bodies such as the American Diabetes Association recommend a glycated haemoglobin (HbA1c) target of < 7%,2 only around 20% of adults with type 1 diabetes under specialist supervision in Australian centres achieve this goal (data from the Australian National Diabetes Information Audit and Benchmarking Survey; Associate Professor Jeff Flack, Director, Diabetes Centre, Bankstown–Lidcombe Hospital, NSW, personal communication).

  • H David McIntyre

  • Mater Health Services, Brisbane, QLD.


Competing interests:

I am Director of the Queensland Diabetes Centre, which runs regular DAFNE courses, and President of the DAFNE Association of Australia, a not-for-profit association which promotes and disseminates the DAFNE method and has received funding from Novo Nordisk (Australia) and Abbott Australasia. I have also received speaker fees and assistance in attending meetings from Novo Nordisk and Eli Lilly Australia, manufacturers of insulin products.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.